{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE292nnn/GSE292717/"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Transcriptomics"],"species":["Homo sapiens"],"gds_type":["Expression profiling by high throughput sequencing"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292717"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"Super-enhancers-driven SOX4/SMAD3 enhances AXL signaling via membrane phospholipid remodeling to accelerate leukemia progression [RNA-Seq]","description":"Cancer often involves aberrant epigenetic activation. In CML-BP, super - enhancer - driven SOX4 and SMAD3 form an auto - regulatory axis. They co - regulate epigenome, activate AXL - related pathways, and mediate membrane phospholipid remodeling. Bemcentinib, an AXL inhibitor, can inhibit CML - BP progression. SOX4/SMAD3 are key factors and Bemcentinib a potential therapy.","dates":{"publication":"2026/05/15"},"accession":"GSE292717","cross_references":{"GSM":["GSM9034437","GSM9034436","GSM9034435","GSM9034434","GSM8864130","GSM8864137","GSM8864115","GSM8864138","GSM8864116","GSM8864135","GSM8864113","GSM8864114","GSM8864136","GSM8864133","GSM8864111","GSM8864112","GSM8864134","GSM8864131","GSM8864132","GSM8864110","GSM8864119","GSM8864117","GSM8864139","GSM8864118","GSM8864140","GSM8864126","GSM8864127","GSM8864105","GSM8864124","GSM8864125","GSM8864122","GSM8864123","GSM8864120","GSM8864121","GSM9034439","GSM9034438","GSM8864108","GSM8864109","GSM8864106","GSM8864128","GSM8864129","GSM8864107"],"GPL":["29480"],"GSE":["292717"],"taxon":["Homo sapiens"],"PMID":["[41721601]"]}}